within Pharmacolibrary.Drugs.ATC.G;

model G03DA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.03333333333333333,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Hydroxyprogesterone is a synthetic derivative of progesterone, primarily used for the prevention of recurrent preterm birth in pregnant women with a history of preterm delivery. Historically, it has also been used in hormone therapy and certain gynecological disorders. Hydroxyprogesterone caproate is approved for use in some countries, including the US, but its approval status may vary globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for hydroxyprogesterone caproate in healthy non-pregnant and pregnant women after intramuscular injection.</p><h4>References</h4><ol><li><p>Sharma, S, et al., &amp; Venkataramanan, R (2016). Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation. <i>British journal of clinical pharmacology</i> 82(4) 1084–1093. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12990&quot;>10.1111/bcp.12990</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27133963/&quot;>https://pubmed.ncbi.nlm.nih.gov/27133963</a></p></li><li><p>Onsrud, M, et al., &amp; Kjørstad, K (1985). Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function. <i>Acta obstetricia et gynecologica Scandinavica</i> 64(6) 519–523. DOI:<a href=&quot;https://doi.org/10.3109/00016348509156732&quot;>10.3109/00016348509156732</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2932883/&quot;>https://pubmed.ncbi.nlm.nih.gov/2932883</a></p></li><li><p>Shaik, IH, et al., &amp; Venkataramanan, R (2016). Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 46(2) 169–174. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2015.1057547&quot;>10.3109/00498254.2015.1057547</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26153441/&quot;>https://pubmed.ncbi.nlm.nih.gov/26153441</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03DA03;
